Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors

Inflammation parameters were verified to predict clinical outcomes of metastatic renal cell carcinoma (mRCC) patients treated with tyrosine kinase inhibitors (TKIs). Here, we developed a novel marker, lactate dehydrogenase (tumor burden marker) to lymphocytes (inflammation marker) ratio (LLR), aimed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pathology oncology research 2020-04, Vol.26 (2), p.1319-1324
Hauptverfasser:	Li, Tao, Li, Heng, Xie, Sheng, Tan, Yan, Xie, Zi-Ping, Li, Wen-Yi, Ai, Fen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Clinical outcomes Dehydrogenase Dehydrogenases Female Humans Immunology Inhibitors Kidney cancer Kidney Neoplasms - blood Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology L-Lactate dehydrogenase L-Lactate Dehydrogenase - blood Lactic acid Lymphocyte Count Lymphocytes Male Metastases Metastasis Middle Aged Multivariate analysis Oncology Original Article Pathology Prognosis Progression-Free Survival Protein Kinase Inhibitors - therapeutic use Renal cell carcinoma Sensitivity and Specificity Survival Treatment Outcome Tyrosine kinase inhibitors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!